Navigation Links
St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia

The findings provide new insights into genomic basis of methotrexate resistance and differences in methotrexate response

MEMPHIS, Tenn., April 15 /PRNewswire-USNewswire/ -- The first analysis of the genetic determinants of resistance to the anti-cancer drug methotrexate in childhood acute lymphoblastic leukemia (ALL) could offer a pathway to predicting such resistance and treatments to overcome it, according to a St. Jude Children's Research Hospital study.

Besides its use in ALL, methotrexate is widely used to treat other cancers and some autoimmune diseases. However, until the new study there was no valid test for analyzing the genetic basis of resistance. Such genetic analysis is important in childhood ALL because, although 80 percent of children with the disease can be cured, determining the basis of drug resistance in the other 20 percent would help increase the cure rate.

The researchers, led by Dr. William E. Evans, St. Jude hospital director and member of St. Jude Pharmaceutical Sciences, reported their findings in the April 2008 issue of "PLoS Medicine."

Researchers have successfully used laboratory studies of leukemia cells to explore the basis of resistance in other anti-leukemia drugs. However, according to Evans, such in vitro tests have not worked with methotrexate. The researchers analyzed the genetic profiles of St. Jude patients undergoing methotrexate treatment for ALL to identify genes that governed their response to the drug.

In their study of 161 ALL patients, they measured the response to initial methotrexate treatment and then used gene microarray analysis to measure the activity levels of 12,357 genes in the patients. In microarray analysis, researchers apply genetic material from the patients' leukemia cells to small "gene chips" on which samples of thousands of genes are arrayed. Researchers can analyze the reactions on the gene chip to each gene to measure the level of expression for those genes in the patient samples.

"In our analysis, we identified a large number of genes in the treated patients that differed in their expression level at a very significant level statistically," Evans said. "We elected to focus on the 50 most highly significant genes."

Among the genes were those involved in DNA synthesis, its components and repair of DNA. The identity of some of these genes was not surprising because the drug kills leukemia cells by interfering with their ability to replicate their DNA.

When the researchers compared the gene expression patterns of patients who responded well to methotrexate to those who responded poorly, they found distinct gene expression "profiles" among the groups. In further analysis to validate their findings, they found that the profiles predicted methotrexate response in an independent group of patients: Patients with gene expression profiles indicating a good methotrexate response had significantly better five-year, disease-free survival than those with profiles indicating a poor response.

To confirm their findings, the researchers also analyzed the predictive effects of those distinctive profiles in an independent group of 18 patients. They found that the gene expression profiles for the top 50 genes also predicted methotrexate response in those patients.

Further exploration of the genes identified in this study could yield clinical benefits. "Some of these could become potential targets for developing other drugs that would make methotrexate more effective in those children who are resistant," Evans said.

For example, one gene they identified as relevant to resistance produces a protein that transports the drug out of the leukemia cell. "It might be possible to give a drug along with methotrexate that blocks this transporter, which would make methotrexate more effective without having to give another cytotoxic drug," Evans said.

In further studies, the researchers plan to search for such drug targets. They will also search for subtle genetic differences among patients in the response-related genes in search of inherited genetic differences that might explain gene expression and methotrexate response. Finally, the researchers will explore whether patients who respond poorly to methotrexate have specific gene deletions or other genetic alterations in their leukemia cells that cause such poor response.

The findings broadly confirm the value of such sweeping surveys of gene expression in understanding response to anti-cancer drugs.

"Studies such as these add another piece of evidence that this genome-wide approach is very insightful and helpful and informative," Evans said. "If you simply look for the genes that you think might be important, you are likely to miss a number of genes that are."

Other authors include Deqing Pei, Wenjian Yang, Cheng Cheng, Ching-Hon Pui, Mary Relling, John Panetta and Meyling Cheok (St. Jude); Michael J. Sorich (University of South Australia); Nicolas Pottier (Pole Recherche, France); Leo Kager (St. Anna Children's Hospital, Austria); and Gabriele Stocco (University of Trieste, Italy).

This work was supported by National Institutes of Health grants, a Cancer Center Support Grant, a FM Kirby Clinical Research Professorship from the American Cancer Society and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit

SOURCE St. Jude Children's Research Hospital
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
2. Cardiac Safety Study of Stinger S-200 Published
3. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
4. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
5. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
8. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
9. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women
10. Study Shows Intradigms RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models
11. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
Post Your Comments:
(Date:10/12/2015)... 12, 2015  CME Group,s Center for Innovation ... of Theranos, is the 11 th recipient of the ... revolutionary blood diagnostics company, Theranos , to change health ... a new era of preventive care. CME Group will present ... Conference in Naples, Florida , on ...
(Date:10/12/2015)... 12, 2015 --> ... Review, H2 2015 market research report provides data ... by identifying new targets and MOAs to produce ... . --> . ... across 62 pages, analyzing 6 companies, 8 drug ...
(Date:10/12/2015)... October 12, 2015 --> ... on the global vital signs monitoring devices market in its ... Analysis and Opportunity Assessment 2015-2025." The global vital signs monitoring ... of 9.5% and 9.2% in terms of value and volume, ... FMI offers major insights in detail in this report. ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... Debbie Vereb has been named the organization’s Executive Vice President of Operations, and ... hired to key leadership roles in the company. , Debbie Vereb’s appointment to ...
(Date:10/13/2015)... ... 13, 2015 , ... Curly Hair Solutions® is thrilled to ... an exhibition featuring the newest products and services to hit the market for ... more excited to unveil their recent partnership with Trade Secrets, a leading Canadian ...
(Date:10/13/2015)... , ... October 13, 2015 ... ... LLC presented results from GyencoloGeneTM, the world’s first commercially-available next-generation sequencing laboratory ... FIGO World Congress of Gynecology and Obstetrics in Vancouver, BC, Canada. ...
(Date:10/13/2015)... NY (PRWEB) , ... October 13, 2015 , ... ... her award winning programs Elder Care Doula Training and End of Life ... elderly in a holistic model, physically, spiritually and emotionally. Based on her ...
(Date:10/12/2015)... ... October 13, 2015 , ... Career Step, ... the release of its new Professional Medical Coding and Billing with Applied PCS ... ICD-10-CM and ICD-10-PCS code sets, earn the Certified Professional Coder (CPC) and Certified ...
Breaking Medicine News(10 mins):